The Heartpod Implantable Heart Failure Therapy System

详细信息    查看全文

• 作者：Antony S. Walton ; Henry Krum
• 关键词：Leiomyosarcoma ; Neoplasm metastasis ; Transoesophageal echocardiography
• 刊名：Heart, Lung and Circulation
• 出版年：2005
• 出版时间：2005
• 年：2005
• 卷：14
• 期：2, Supplement 1
• 页码：S31-S33
• 全文大小：276 K

文摘

Following myocardial infarction, progressive deterioration of left ventricular function often follows, leading eventually to overt heart failure. In the myocardium, there is increased expression of insulin-like growth factor I (IGF-I) mRNA, protein and receptor levels, particularly in the peri-infarct zone, suggesting that IGF-I has a role to play in post-infarct cardiac structure and function. In this study, we examine the effects of exogenous IGF-I on cardiac function.

ss=""h4"">Methods.

Intrapericardial IGF-I (150 μg/kg/d, n = 3) or vehicle (sterile saline, n = 3) was administered to sheep in chronic heart failure and the results of intrapericardial delivery compared with those of subcutaneous delivery. Left ventricular ejection fraction (EF) was measured to assess cardiac performance. Concentrations of plasma IGF-I were quantified by radioimmunoassay.

ss=""h4"">Results.

Intrapericardial delivery of IGF-I resulted in a rapid and sustained increase (P < 0.001) in EF, which remained elevated 14 days after cessation of treatment. Subcutaneous IGF-I treatment did not affect EF. Both subcutaneous and intrapericardial IGF-I administration increased concentrations of plasma IGF-I, although concentrations declined prior to the cessation of treatment.

ss=""h4"">Conclusions.

We conclude that the higher concentration of IGF-I in the myocardium, which results from intrapericardial delivery significantly increases EF in chronic heart failure but that subcutaneous delivery of IGF-I does not.